

JAK2/3 (Phospho Tyr966/939) Antibody

CatalogNo: YP1214

Key Features

Host Species

- Rabbit

Reactivity

- Human:Y966/939,Mouse:Y966/935,Rat:Y966/935

Applications

- WB,ELISA,IHC

Isotype

- IgG

Storage

Storage* -15°C to -25°C/1 year(Do not lower than -25°C)

Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Recommended Dilution Ratios

WB 1:500-2000

IHC 1:50-300

ELISA 1:2000-20000

Basic Information

Clonality Polyclonal

Immunogen Information

Immunogen Synthesized Phospho peptide derived from human JAK2/3.at AA range: T966

Specificity This antibody detects endogenous levels of JAK2/3 only when phosphorylated at Tyr966/939.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):MEyLG

| Target Information

Gene name JAK2 JAK3

Protein Name JAK2/3


Organism	Gene ID	UniProt ID
Human	1132 ; 1124 ;	O60674 ; P52333 ;

Cellular Localization Endomembrane system ; Peripheral membrane protein . Cytoplasm . Nucleus .


Tissue specificity Ubiquitously expressed throughout most tissues.

Function Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,Disease:Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.,Disease:Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.,Disease:Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.,Disease:Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.,Disease:Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.,Disease:Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.,Domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.,Function:Plays a role in leptin signaling and control of body weight (By similarity). Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.,PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.,similarity:Contains 1 FERM domain.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 SH2 domain.,subcellular location:Wholly intracellular, possibly membrane associated.,subunit:Interacts with SIRPA and SH2B1 (By similarity). Interacts with IL23R, SKB1 and STAM2.,tissue specificity:Expressed in blood, bone marrow and lymph node.,


Validation Data



Western Blot analysis of 1,mouse-liver 2,hela 3,mouse-brain cells using primary antibody diluted at 1:1000 (4°C overnight). Secondary antibody:Goat Anti-rabbit IgG IRDye 800 (diluted at 1:5000, 25°C, 1 hour)



Western Blot analysis of hela cells using primary antibody diluted at 1:1000 (4°C overnight). Secondary antibody:Goat Anti-rabbit IgG IRDye 800 (diluted at 1:5000, 25°C, 1 hour)



Immunohistochemical analysis of paraffin-embedded human liver cancer. 1, Antibody was diluted at 1:200 (4°C overnight). 2, Tris-EDTA,pH9.0 was used for antigen retrieval. 3,Secondary antibody was diluted at 1:200 (room temperature, 45min).

Contact information

Orders: order@immunoway.com
Support: tech@immunoway.com
Telephone: 877-594-3616 (Toll Free), 408-747-0185
Website: <http://www.immunoway.com>
Address: 2200 Ringwood Ave San Jose, CA 95131 USA



Please scan the QR code to access additional product information:
JAK2/3 (Phospho Tyr966/939) Antibody